Literature DB >> 2410632

Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies.

J H Mathews, J T Roehrig, D W Trent.   

Abstract

We have previously characterized with monoclonal antibodies (MAbs) seven unique epitopes on the two envelope glycoproteins of Venezuelan equine encephalomyelitis (VEE) virus vaccine strain TC-83. The epitopes important in protection from VEE virus infection were determined in passive antibody transfer studies, with virulent VEE (Trinidad donkey) virus as the challenge virus. Selected high-avidity MAbs to the three major protective epitopes (E2c, E1b, and E1d) were assayed for in vitro complement activity. All three fixed murine complement to high titer. Limited pepsin digestion of the anti-E2c in the presence of cysteine resulted in a rapid decrease and complete loss of complement-fixing ability by 2 h, but the majority of mice, except at the lowest dilution of MAb, were protected until the Fc termini were cleaved at 3 h. Anti-E2c F(ab')2 would neutralize VEE (Trinidad donkey) virus more efficiently than either Fab' or Fab; none of the fragments would fix complement or was effective in passive protection. C5-deficient mice and mice depleted of C3 with cobra venom factor were still protected from VEE (Trinidad donkey) virus challenge after passive transfer of either anti-E2c or anti-E1b MAb. The results show that the anti-E2c MAb mediates neutralization through bivalent binding at a critical site on the virion and that Fc effector functions, other than complement, are necessary for protection. Although the ability of the anti-E2c MAb to fix complement was associated with its ability to protect in vivo, no direct cause-and-effect relationship was found. Since the epitope defined by the anti-E1d antibody is found on the cell membrane, but is not expressed on the infectious virion, protection in mice was most likely mediated at the cellular level, possibly by inhibition of the final stages of virion maturation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410632      PMCID: PMC255017     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Complement-fixing IgG1 constitutes a new subclass of mouse IgG.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Nature       Date:  1979-10-11       Impact factor: 49.962

2.  The structural basis for the functional versatility of immunoglobulin G1.

Authors:  K J Dorrington
Journal:  Can J Biochem       Date:  1978-12

3.  Topographical analysis of viral epitopes using monoclonal antibodies: mechanism of virus neutralization.

Authors:  R J Massey; G Schochetman
Journal:  Virology       Date:  1981-11       Impact factor: 3.616

4.  Lysis of retroviruses with monoclonal antibodies against viral envelope proteins.

Authors:  S Oroszlan; R C Nowinski
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

5.  The role of complement in viral infections. III. Activation of the classical and alternative complement pathways by Sindbis virus.

Authors:  R L Hirsch; J A Winkelstein; D E Griffin
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

6.  Expression of influenza A virus internal antigens on the surface of infected P815 cells.

Authors:  J W Yewdell; E Frank; W Gerhard
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

7.  Role of complement in viral infections: participation of terminal complement components (C5 to C9) in recovery of mice from Sindbis virus infection.

Authors:  R L Hirsch; D E Griffin; J A Winkelstein
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

8.  Role of Fc fragments in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections.

Authors:  J E Oakes; R N Lausch
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

9.  Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody.

Authors:  J G Patrick Sissons; R D Schreiber; L H Perrin; N R Cooper; H J Müller-Eberhard; M B Oldstone
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

10.  Regulation of the immune response. I. The potentiation of in vivo and in vitro immune responses by Fc fragments.

Authors:  E L Morgan; S M Walker; M L Thoman; W O Weigle
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

View more
  25 in total

1.  A synthetic peptide to the E glycoprotein of Murray Valley encephalitis virus defines multiple virus-reactive T- and B-cell epitopes.

Authors:  J H Mathews; J T Roehrig; J R Brubaker; A R Hunt; J E Allan
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.

Authors:  I Ourmanov; M Bilska; V M Hirsch; D C Montefiori
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies.

Authors:  Jason Porta; Joyce Jose; John T Roehrig; Carol D Blair; Richard J Kuhn; Michael G Rossmann
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

5.  Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.

Authors:  Ann R Hunt; Richard A Bowen; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  Virology       Date:  2011-04-13       Impact factor: 3.616

6.  Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Authors:  S H Pincus; R Cole; R Ireland; F McAtee; R Fujisawa; J Portis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus.

Authors:  S C Cheung; B Dietzschold; H Koprowski; A L Notkins; R F Rando
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice.

Authors:  J Stanley; S J Cooper; D E Griffin
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

10.  Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains.

Authors:  Lyn M O'Brien; Cindy D Underwood-Fowler; Sarah A Goodchild; Amanda L Phelps; Robert J Phillpotts
Journal:  Virol J       Date:  2009-11-19       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.